NIPER-Raebareli Partners with Lofty Laboratories to Commercialise Biotech Innovation

As part of the agreement, Lofty Laboratories will adopt an industry-ready technology developed at NIPER-Raebareli for further development and commercialization.

In a significant boost to India's pharmaceutical and biotechnology innovation ecosystem, the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli has entered into a strategic partnership with Hyderabad-based Lofty Laboratories through the signing of a Memorandum of Understanding (MoU), Confidential Disclosure Agreement (CDA), and Technology Transfer Agreement aimed at accelerating research commercialization and industry-oriented innovation.

The collaboration marks an important step toward strengthening academia-industry partnerships in India's rapidly expanding life sciences sector and is expected to facilitate the commercialization of indigenous technologies developed at NIPER-Raebareli.

Officials said the partnership would foster multidirectional collaboration in research, technology development, innovation transfer and industrial-scale application of advanced pharmaceutical and biotechnology solutions.

Indigenous Technology Developed at NIPER to Enter Commercial Production

As part of the agreement, Lofty Laboratories will adopt an industry-ready technology developed at NIPER-Raebareli for further development and commercialization.

The technology, developed under the Institute's Centre of Excellence on Novel Drug Delivery Systems (CoE-NDDS), focuses on advanced gel-staining agents used extensively in biological and molecular research.

Experts say gel-staining agents are critical tools in laboratories worldwide and are widely used in:

• Gene-related research

• Cancer studies

• DNA and RNA analysis

• Molecular diagnostics

• Nucleic acid research

• Biotechnology applications

Currently, a large proportion of advanced biological reagents and laboratory consumables are imported, often making research expensive for Indian institutions and laboratories.

The indigenous commercialization of such technologies is expected to reduce costs significantly while enhancing India's self-reliance in critical biotech research materials.

Move Expected to Reduce Research Costs Across India

Speaking during the signing ceremony, Prof. Nihar Ranjan, Head of CoE-NDDS, said the commercialization of the technology could substantially lower the cost of gel-staining agents used globally in biological research.

"Commercialization of the present technology would significantly reduce the cost of gel-staining agents extensively used worldwide in biology-related research, especially in studies involving genes, cancer and other nucleic acid-related diseases," he said.

He added that indigenous production of such advanced scientific reagents would contribute meaningfully to strengthening India's pharmaceutical and biotechnology sectors.

Industry experts note that cost-effective domestic production of laboratory research materials could play a major role in supporting India's growing biotechnology startup ecosystem, academic research institutions and pharmaceutical R&D infrastructure.

Strong Push for Academia-Industry Collaboration

NIPER-Raebareli Director Prof. Shubhini A. Saraf described the agreement as a major milestone in building long-term collaborative research and commercialization frameworks between academia and industry.

According to Prof. Saraf, the partnership would allow both organizations to complement each other's research strengths while jointly participating in advanced pharmaceutical and biotechnology development programmes.

"The MoU and technology transfer agreement will enable both institutions to complement each other's research programs in multiple ways," she said.

She specifically highlighted collaborative opportunities within the activities of the Institute's Centre of Excellence on Novel Drug Delivery Systems (CoE-NDDS).

Prof. Saraf also expressed optimism that multiple additional technologies currently under development at the Centre of Excellence could become ready for transfer and commercialization by the end of the year.

India's Pharmaceutical Innovation Ecosystem Expanding Rapidly

The collaboration comes at a time when India is intensifying efforts to strengthen domestic pharmaceutical innovation, biotechnology manufacturing and translational research under the broader vision of "Atmanirbhar Bharat" and innovation-led economic growth.

India currently ranks among the world's largest producers of generic medicines and vaccines, while the biotechnology sector is witnessing rapid expansion driven by:

• Increased research investment

• Growth of biotech startups

• Expansion of genomic research

• AI-driven drug discovery

• Rising demand for molecular diagnostics

• Government-backed innovation initiatives

Experts believe stronger academia-industry collaborations will be critical for translating laboratory research into commercially viable healthcare and biotech solutions.

Technology Transfer Emerging as Key Driver of Innovation Economy

The signing of the Technology Transfer Agreement reflects a broader shift in India's higher education and scientific research ecosystem toward commercialization-focused innovation.

Technology transfer agreements allow research institutions to move promising laboratory-developed technologies into industrial production, thereby accelerating:

• Product development

• Industrial innovation

• Startup incubation

• Intellectual property commercialization

• Affordable scientific manufacturing

• Employment generation in high-tech sectors

Analysts say such partnerships can help bridge the longstanding gap between academic research and commercial application in India's science and technology ecosystem.

NIPER-Raebareli Strengthening Its Innovation Profile

NIPER-Raebareli, one of India's premier pharmaceutical education and research institutions, has increasingly focused on advanced drug delivery systems, translational pharmaceutical research and biotech innovation.

The Institute's Centre of Excellence on Novel Drug Delivery Systems has been working on technologies related to:

• Advanced formulations

• Drug delivery platforms

• Biomedical applications

• Research reagents

• Pharmaceutical innovation

With multiple technologies reportedly nearing commercialization readiness, the Institute is positioning itself as an emerging hub for pharmaceutical and biotechnology innovation in India.

The partnership with Lofty Laboratories is expected to further accelerate this innovation ecosystem while opening new opportunities for collaborative industrial research and technology deployment.